HK1164311A1 - Certain crystalline hydrates, pharmaceutical compositions thereof and use thereof - Google Patents

Certain crystalline hydrates, pharmaceutical compositions thereof and use thereof

Info

Publication number
HK1164311A1
HK1164311A1 HK12105009.4A HK12105009A HK1164311A1 HK 1164311 A1 HK1164311 A1 HK 1164311A1 HK 12105009 A HK12105009 A HK 12105009A HK 1164311 A1 HK1164311 A1 HK 1164311A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
crystalline hydrates
certain crystalline
prime
hydrates
Prior art date
Application number
HK12105009.4A
Other languages
English (en)
Inventor
Feng Que
Ying Wang
Original Assignee
Sichuan Beilike Biotechnology Ltd Liability Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Beilike Biotechnology Ltd Liability Co filed Critical Sichuan Beilike Biotechnology Ltd Liability Co
Publication of HK1164311A1 publication Critical patent/HK1164311A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12105009.4A 2009-11-04 2012-05-22 Certain crystalline hydrates, pharmaceutical compositions thereof and use thereof HK1164311A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25792409P 2009-11-04 2009-11-04
PCT/CN2010/078377 WO2011054292A1 (en) 2009-11-04 2010-11-03 Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof

Publications (1)

Publication Number Publication Date
HK1164311A1 true HK1164311A1 (en) 2012-09-21

Family

ID=43969571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105009.4A HK1164311A1 (en) 2009-11-04 2012-05-22 Certain crystalline hydrates, pharmaceutical compositions thereof and use thereof

Country Status (11)

Country Link
US (1) US8916567B2 (xx)
EP (1) EP2496563A4 (xx)
JP (1) JP2013510098A (xx)
KR (1) KR20130028703A (xx)
CN (1) CN102256951B (xx)
AU (1) AU2010314593B2 (xx)
BR (1) BR112012010635A2 (xx)
HK (1) HK1164311A1 (xx)
RU (1) RU2012122767A (xx)
WO (1) WO2011054292A1 (xx)
ZA (1) ZA201203531B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364240B (zh) * 2012-06-08 2017-02-22 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
CN107456442A (zh) * 2016-06-03 2017-12-12 四川赛卓药业股份有限公司 一种噁唑烷酮化合物的亚微乳注射剂及其制备方法和用途
CN107648181B (zh) * 2016-07-25 2021-05-04 广东赛法洛药业有限公司 一种利他唑酮磷脂复合物及其制备方法和应用
CN112409285A (zh) * 2020-11-30 2021-02-26 山东金城昆仑药业有限公司 噁唑烷酮类化合物的晶型及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2119556C (en) * 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
AU707748B2 (en) * 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1999002525A1 (en) * 1997-07-11 1999-01-21 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
GB9821938D0 (en) * 1998-10-09 1998-12-02 Zeneca Ltd Chemical compounds
CN1155585C (zh) * 2001-12-19 2004-06-30 中国医学科学院医药生物技术研究所 3,5－取代噁唑烷酮衍生物及其制备方法和应用
AU2004256085B2 (en) * 2003-07-02 2007-12-06 Kyorin, Pharmaceutical Co., Ltd. Cyclopropyl Group Substituted Oxazolydinone Antibiotics and Derivatives Thereof
EP1745028A2 (en) * 2004-06-29 2007-01-24 Teva Pharmaceutical Industries Ltd Solid forms of linezolid and processes for preparation thereof
CN100538355C (zh) * 2007-03-19 2009-09-09 四川贝力克生物技术有限责任公司 3,5-取代噁唑烷酮类化合物的纯度的检测方法
CN100582749C (zh) * 2007-03-19 2010-01-20 四川贝力克生物技术有限责任公司 3,5-取代噁唑烷酮类化合物的含量测定方法
CN100473385C (zh) * 2007-03-19 2009-04-01 四川贝力克生物技术有限责任公司 3,5-取代噁唑烷酮类化合物的溶解方法

Also Published As

Publication number Publication date
EP2496563A4 (en) 2013-04-03
RU2012122767A (ru) 2013-12-10
US8916567B2 (en) 2014-12-23
WO2011054292A1 (en) 2011-05-12
KR20130028703A (ko) 2013-03-19
BR112012010635A2 (pt) 2018-03-20
US20110136822A1 (en) 2011-06-09
JP2013510098A (ja) 2013-03-21
EP2496563A1 (en) 2012-09-12
AU2010314593A1 (en) 2012-06-14
CN102256951B (zh) 2013-07-17
AU2010314593B2 (en) 2015-05-21
CN102256951A (zh) 2011-11-23
ZA201203531B (en) 2013-07-31

Similar Documents

Publication Publication Date Title
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
GEP20135992B (en) Sulfonamide derivatives
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
GEP20125579B (en) Novel crystalline form vi of agomelatine, preparation method thereof and pharmaceutical compositions containing same
MY153985A (en) Aminotriazole derivatives as alx agonists
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
MX2010003224A (es) Derivados de biaril sulfonamida.
GEP20135882B (en) Crystal form of phenylamino pyrimidine derivatives
IN2012DN03337A (xx)
MY163979A (en) Non-nucleoside reverse transcriptase inhibitors
MX342440B (es) Derivados fluorados de aminotriazol.
TW200833324A (en) Sulfonamide derivatives
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
UA109037C2 (xx) Триазолопіридини
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
MX2010001742A (es) Nuevos derivados de piperazina-amida.
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
RS53900B1 (en) CRYSTAL FORMS OF HYDROCHLORIDE SALTS (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONYL) -2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDENO [2,1-B] PIRIDIN-6-CARBONITRILA AND THEIR USE AS A HSD INHIBITOR 1
TW200738627A (en) Trialkylsilyl-indoles
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
PT2448933E (pt) Ácido trans-4-[[(5s)-5-[[[3,5- bis(trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5- il)amino]-2,3,4,5-tetra-hidro-7,9-dimetil-1h-1-benzazepin- 1-il]metil]-ciclo-hexanocarboxílico

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171103